Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency
NCT07016802Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GenSci134 in adult growth hormone deficiency (AGHD) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Incidence and severity of adverse events and serious adverse events at Month 3. Started Jun 2025; status: recruiting.
02
Drugs
GenSci134
03
Conditions
adult growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NCT07016802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016802.